SPIRIT III Results Reaffirm Strong Performance Of Boston Scientific PROMUS(TM) And TAXUS(R) Express(R) Stents
May 15th, 2008 by 
admin Boston Scientific Corporation (NYSE: BSX) welcomed two-year results from the SPIRIT threesome clinical trial, which move to reaffirm the proven long-term country and effectualness of the market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System and fortify the ontogeny embody of constructive clinical grounds for the XIENCE(TM) V (PROMUS(TM)) Everolimus-Eluting Coronary Stent System.
Posted in Cardiology | 